Haixiang Pharmaceutical

Zhejiang Haixiang Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the development, manufacture, and sale of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company is a global leader in the production of clindamycin-based antibiotics and maintains a significant presence in the cardiovascular, antidiabetic, and central nervous system therapeutic areas. Beyond its pharmaceutical portfolio, Haixiang operates a robust fine chemicals division focused on reactive dyes. The company serves as a strategic CDMO partner for several multinational pharmaceutical corporations, leveraging its large-scale, GMP-compliant manufacturing facilities in Zhejiang province. Listed on the Shenzhen Stock Exchange, it continues to expand its international footprint through high-quality chemical synthesis and integrated production chains.